TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prophylactic Probiotics for the Prevention of Sepsis and NEC in Premature Infants in Colombia. A Randomized Double-Blind, Multicenter Trial
Brief Summary: This study tries to determine whether the oral administration of a specific probiotic (good bacteria) in premature infants hospitalized in a neonatal intensive care unit may prevent infections and the development of a severe inflammatory disease of the bowel called necrotizing enterocolitis. The investigators propose that premature infants not given probiotics will colonize their gut with bad bacterias and develop infection.


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lactobacillus reuteri | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus reuteri; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 1
B: Arm Label: Maltodextrin; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Probiotic supplementation | Arm Label: Probiotic B lactis/B longum; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Probiotic supplementation | Arm Label: Probiotic B longum; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Probiotic supplementation | Arm Label: Probiotic B lactis; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Probiotic supplementation | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotic supplementation; Assigned to Arm(s): Maltodextrin, Probiotic B lactis, Probiotic B lactis/B longum, Probiotic B longum
C: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: infloran | Intervention Type: DIETARY_SUPPLEMENT; Name: infloran; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: infloran; Assigned to Arm(s): 2
D: Arm Label: Lactobacillus PS11603 & Bifidobacterium PS10402; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lactobacillus PS11603 & Bifidobacterium PS10402 | Arm Label: Placebo; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus PS11603 & Bifidobacterium PS10402; Assigned to Arm(s): Lactobacillus PS11603 & Bifidobacterium PS10402 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prophylactic Probiotics for the Prevention of Sepsis and NEC in Premature Infants in Colombia. A Randomized Double-Blind, Multicenter Trial
Brief Summary: This study tries to determine whether the oral administration of a specific probiotic (good bacteria) in premature infants hospitalized in a neonatal intensive care unit may prevent infections and the development of a severe inflammatory disease of the bowel called necrotizing enterocolitis. The investigators propose that premature infants not given probiotics will colonize their gut with bad bacterias and develop infection.


Options:
A: Arm Label: Probiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotics | Arm Label: Probiotics + Dietary counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and probiotics | Arm Label: Dietary counseling + placebo; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and placebo | Arm Label: Prebiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Prebiotics | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo capsules | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary counselling and placebo; Assigned to Arm(s): Dietary counseling + placebo | Intervention Type: BEHAVIORAL; Name: Dietary counselling and probiotics; Assigned to Arm(s): Probiotics + Dietary counseling | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo capsules; Assigned to Arm(s): Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotics; Assigned to Arm(s): Probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Prebiotics; Assigned to Arm(s): Prebiotics
B: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: infloran | Intervention Type: DIETARY_SUPPLEMENT; Name: infloran; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: infloran; Assigned to Arm(s): 2
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lactobacillus reuteri | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus reuteri; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 1
D: Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotics supplementation until weight reaches 1800g (Bifidobacterium Longum and Lactobacillus GG ); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study of Golimumab (CNTO 148) Administered in Combination With Methotrexate (MTX) in Patients With Active Rheumatoid Arthritis
Brief Summary: The purpose of this study is to evaluate the safety and effectiveness of golimumab in patients with active rheumatoid arthritis despite Methotrexate therapy. Another objective is to evaluate the pharmacokinetics of golimumab.


Options:
A: Arm Label: Sequence 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: CP-690,550 or Placebo | Arm Label: Sequence 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CP-690,550 or Placebo; Assigned to Arm(s): Sequence 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sequence 2
B: Arm Label: Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Biological: tocilizumab, Drug: methotrexate, Biological: 23-Valent Pneumococcal Polysaccharide Vaccine, Biological: Tetanus Toxoid Adsorbed Vaccine | Arm Label: Tocilizumab + Methotrexate; Type: EXPERIMENTAL; Interventions: Biological: tocilizumab, Drug: methotrexate, Biological: 23-Valent Pneumococcal Polysaccharide Vaccine, Biological: Tetanus Toxoid Adsorbed Vaccine | Intervention Type: BIOLOGICAL; Name: tocilizumab; Assigned to Arm(s): Methotrexate, Tocilizumab + Methotrexate | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): Methotrexate, Tocilizumab + Methotrexate | Intervention Type: BIOLOGICAL; Name: 23-Valent Pneumococcal Polysaccharide Vaccine; Assigned to Arm(s): Methotrexate, Tocilizumab + Methotrexate | Intervention Type: BIOLOGICAL; Name: Tetanus Toxoid Adsorbed Vaccine; Assigned to Arm(s): Methotrexate, Tocilizumab + Methotrexate
C: Arm Label: Certolizumab Pegol; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol; Assigned to Arm(s): Certolizumab Pegol
D: Arm Label: CNTO 148 50 mg + methotrexate; Type: EXPERIMENTAL; Interventions: Drug: CNTO 148, Drug: Methotrexate (MTX) | Arm Label: CNTO 148 100 mg + methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate (MTX) | Arm Label: Placebo + methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate (MTX) | Intervention Type: DRUG; Name: CNTO 148; Assigned to Arm(s): CNTO 148 50 mg + methotrexate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + methotrexate | Intervention Type: DRUG; Name: Methotrexate (MTX); Assigned to Arm(s): CNTO 148 100 mg + methotrexate, CNTO 148 50 mg + methotrexate, Placebo + methotrexate

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study of Golimumab (CNTO 148) Administered in Combination With Methotrexate (MTX) in Patients With Active Rheumatoid Arthritis
Brief Summary: The purpose of this study is to evaluate the safety and effectiveness of golimumab in patients with active rheumatoid arthritis despite Methotrexate therapy. Another objective is to evaluate the pharmacokinetics of golimumab.


Options:
A: Arm Label: CNTO 148 50 mg + methotrexate; Type: EXPERIMENTAL; Interventions: Drug: CNTO 148, Drug: Methotrexate (MTX) | Arm Label: CNTO 148 100 mg + methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate (MTX) | Arm Label: Placebo + methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate (MTX) | Intervention Type: DRUG; Name: CNTO 148; Assigned to Arm(s): CNTO 148 50 mg + methotrexate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + methotrexate | Intervention Type: DRUG; Name: Methotrexate (MTX); Assigned to Arm(s): CNTO 148 100 mg + methotrexate, CNTO 148 50 mg + methotrexate, Placebo + methotrexate
B: Intervention Type: DRUG; Name: Certolizumab Pegol; Assigned to Arm(s): N/A
C: Arm Label: 1a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate | Arm Label: 1b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate, Drug: Placebo | Arm Label: 2a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate, Drug: Placebo | Arm Label: 2b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 1a, 1b, 2a | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1a, 1b, 2a, 2b | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1b, 2a
D: Arm Label: Golimumab (CNTO 148) with Methotrexate (MTX); Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Drug: MTX | Arm Label: Infliximab with MTX; Type: EXPERIMENTAL; Interventions: Drug: MTX, Drug: Infliximab | Arm Label: Placebo with MTX; Type: PLACEBO_COMPARATOR; Interventions: Drug: MTX, Drug: Placebo | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): Golimumab (CNTO 148) with Methotrexate (MTX) | Intervention Type: DRUG; Name: MTX; Assigned to Arm(s): Golimumab (CNTO 148) with Methotrexate (MTX), Infliximab with MTX, Placebo with MTX | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo with MTX | Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): Infliximab with MTX

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study of Golimumab (CNTO 148) Administered in Combination With Methotrexate (MTX) in Patients With Active Rheumatoid Arthritis
Brief Summary: The purpose of this study is to evaluate the safety and effectiveness of golimumab in patients with active rheumatoid arthritis despite Methotrexate therapy. Another objective is to evaluate the pharmacokinetics of golimumab.


Options:
A: Arm Label: CNTO 148 50 mg + methotrexate; Type: EXPERIMENTAL; Interventions: Drug: CNTO 148, Drug: Methotrexate (MTX) | Arm Label: CNTO 148 100 mg + methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate (MTX) | Arm Label: Placebo + methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate (MTX) | Intervention Type: DRUG; Name: CNTO 148; Assigned to Arm(s): CNTO 148 50 mg + methotrexate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + methotrexate | Intervention Type: DRUG; Name: Methotrexate (MTX); Assigned to Arm(s): CNTO 148 100 mg + methotrexate, CNTO 148 50 mg + methotrexate, Placebo + methotrexate
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1, 2, 3
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept , Methotrexate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide | Intervention Type: DRUG; Name: Etanercept , Methotrexate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide; Assigned to Arm(s): 2
D: Arm Label: 1a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate | Arm Label: 1b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate, Drug: Placebo | Arm Label: 2a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate, Drug: Placebo | Arm Label: 2b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 1a, 1b, 2a | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1a, 1b, 2a, 2b | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1b, 2a

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Exercise Intervention to Prevent Recurrent GDM
Brief Summary: Women diagnosed with gestational diabetes mellitus (GDM) are at substantially increased risk of developing type 2 diabetes and obesity, currently at epidemic rates in the United States. GDM, therefore, identifies a population of women at high risk of developing type 2 diabetes and thus provides an excellent opportunity to intervene years before the development of this disorder. It is well recognized that acute as well as chronic physical activity reduce fasting plasma glucose as well as improve glucose tolerance in type 2 diabetes. Recent studies have suggested that women with higher levels of physical activity have reduced risk of GDM. Therefore, we will test the hypothesis that an exercise intervention is an effective tool for preventing GDM among women with a history of GDM.


Options:
A: Arm Label: Nutritional counseling & self blood glucose monitoring; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: nutritional counseling, Behavioral: self blood glucose monitoring | Arm Label: No treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: nutritional counseling; Assigned to Arm(s): Nutritional counseling & self blood glucose monitoring | Intervention Type: BEHAVIORAL; Name: self blood glucose monitoring; Assigned to Arm(s): Nutritional counseling & self blood glucose monitoring
B: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Arm Label: Wait-listed control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): intervention
C: Arm Label: Heath & Wellness; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Heath & Wellness | Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity | Intervention Type: BEHAVIORAL; Name: Physical activity; Assigned to Arm(s): Exercise | Intervention Type: BEHAVIORAL; Name: Heath & Wellness; Assigned to Arm(s): Heath & Wellness
D: Arm Label: Diet alone; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Behavioral therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral therapy | Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Other: Exercise | Arm Label: Behavioral therapy and exercise; Type: EXPERIMENTAL; Interventions: Other: Behavioral therapy and exercise | Intervention Type: BEHAVIORAL; Name: Behavioral therapy; Assigned to Arm(s): Behavioral therapy | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise | Intervention Type: OTHER; Name: Behavioral therapy and exercise; Assigned to Arm(s): Behavioral therapy and exercise

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Brief Intervention for Heavy Drinkers - a Randomized Controlled Trial
Brief Summary: The purpose of the study is to determine whether a brief intervention (a short conversation build on the principles of motivational interviewing) is effective in lowering self reported alcohol use in heavy drinkers.


Options:
A: Arm Label: EARLY; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing plus feedback | Arm Label: Video Information; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Video | Arm Label: Informational Brochure; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Informational Brochure | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing plus feedback; Assigned to Arm(s): EARLY | Intervention Type: BEHAVIORAL; Name: Video; Assigned to Arm(s): Video Information | Intervention Type: BEHAVIORAL; Name: Informational Brochure; Assigned to Arm(s): Informational Brochure
B: Arm Label: 1) MI/Family Check-Up; Type: EXPERIMENTAL; Interventions: Behavioral: MI/Family Check-up | Arm Label: 2) MI only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: MI only | Intervention Type: BEHAVIORAL; Name: MI/Family Check-up; Assigned to Arm(s): 1) MI/Family Check-Up | Intervention Type: BEHAVIORAL; Name: MI only; Assigned to Arm(s): 2) MI only
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Brief intervention | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Control group | Intervention Type: OTHER; Name: Brief intervention; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): 2
D: Arm Label: 1 Brief Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief alcohol intervention | Arm Label: 2) Booster; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief alcohol intervention plus booster | Intervention Type: BEHAVIORAL; Name: Brief alcohol intervention; Assigned to Arm(s): 1 Brief Intervention | Intervention Type: BEHAVIORAL; Name: Brief alcohol intervention plus booster; Assigned to Arm(s): 2) Booster

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Enhancing Adherence to an Internet-Mediated Walking Program by Building Online Communities
Brief Summary: The purpose of this study is to determine whether online peer support will increase adherence to an internet-based pedometer walking program.


Options:
A: Arm Label: Enhanced Internet-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored content, Behavioral: Generic Internet-based information, Behavioral: Discussion forum, Behavioral: Behavioral monitoring | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Generic Internet-based information, Behavioral: Discussion forum | Intervention Type: BEHAVIORAL; Name: Tailored content; Assigned to Arm(s): Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Generic Internet-based information; Assigned to Arm(s): Control, Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Discussion forum; Assigned to Arm(s): Control, Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Behavioral monitoring; Assigned to Arm(s): Enhanced Internet-based intervention
B: Arm Label: Family-Centered Empowerment Model; Type: EXPERIMENTAL; Interventions: Other: Family-centered empowerment model | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Control | Intervention Type: OTHER; Name: Family-centered empowerment model; Assigned to Arm(s): Family-Centered Empowerment Model | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
C: Arm Label: Facebook group; Type: EXPERIMENTAL; Interventions: Behavioral: Facebook | Arm Label: Comparison group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Facebook | Intervention Type: BEHAVIORAL; Name: Facebook; Assigned to Arm(s): Comparison group, Facebook group
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Stepping Up to Health | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Stepping Up to Health | Intervention Type: BEHAVIORAL; Name: Stepping Up to Health; Assigned to Arm(s): 1, 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Enhancing Adherence to an Internet-Mediated Walking Program by Building Online Communities
Brief Summary: The purpose of this study is to determine whether online peer support will increase adherence to an internet-based pedometer walking program.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Stepping Up to Health | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Stepping Up to Health | Intervention Type: BEHAVIORAL; Name: Stepping Up to Health; Assigned to Arm(s): 1, 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Heart to Heart (Web-Based Decision Aid), Behavioral: Physician Education Session | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Heart to Heart (Web-Based Decision Aid); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Physician Education Session; Assigned to Arm(s): 1
C: Arm Label: Cardio fit; Type: EXPERIMENTAL; Interventions: Behavioral: CardioFit | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CardioFit; Assigned to Arm(s): Cardio fit
D: Arm Label: Quality improvement program; Type: OTHER; Interventions: Other: multifaceted strategy | Arm Label: Hospital standard treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: multifaceted strategy; Assigned to Arm(s): Quality improvement program

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Ablation vs. Amiodarone for Treatment of Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted ICD/CRTD
Brief Summary: 1. To determine if catheter-based atrial fibrillation (AF) ablation is superior to Amiodarone treatment for symptomatic persistent/permanent AF in ICD/CRTD patients with an impaired left ventricular function.
2. Hypothesis: AF ablation is better than Amiodarone for subjects with symptomatic persistent or permanent AF and impaired LV function in terms of recurrence of AF, quality of life, 6-minute walk distance, EF and total number of hospitalizations.


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Vernakalant (oral) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Vernakalant (oral) | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Vernakalant (oral) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Vernakalant (oral); Assigned to Arm(s): 2, 3, 4
B: Arm Label: Atrial Fibrillation Ablation; Type: EXPERIMENTAL; Interventions: Procedure: Atrial fibrillation ablation | Arm Label: Drug therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Antiarrhythmic drug | Intervention Type: PROCEDURE; Name: Atrial fibrillation ablation; Assigned to Arm(s): Atrial Fibrillation Ablation | Intervention Type: DRUG; Name: Antiarrhythmic drug; Assigned to Arm(s): Drug therapy
C: Arm Label: Propafenone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Propafenone | Arm Label: Dronedarone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dronedarone | Intervention Type: DRUG; Name: Propafenone; Assigned to Arm(s): Propafenone | Intervention Type: DRUG; Name: Dronedarone; Assigned to Arm(s): Dronedarone
D: Arm Label: AF ablation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Atrial Fibrillation ablation | Arm Label: Amiodarone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amiodarone | Intervention Type: PROCEDURE; Name: Atrial Fibrillation ablation; Assigned to Arm(s): AF ablation | Intervention Type: DRUG; Name: Amiodarone; Assigned to Arm(s): Amiodarone

Answer: D